CDC Website CDC Website

To Join the NPIN community or

You are here


Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event -driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages.

Understanding the Mechanisms of Neuropsychiatric Side Effects and Neurological Toxicities of HIV Medicines (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites innovative research grant applications focused on identifying potential mechanisms and risk factors underlying HIV treatment associated neuropsychiatric symptoms and neurological toxicities experienced by some people living with HIV infection. Exploratory and high-risk research projects that may lead to identification of targets for therapeutic interventions or personalized medicine are appropriate for this FOA. Basic and preclinical research in domestic and international settings are of interest.

Computational Models of Immunity (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits applications developing computational models of immunity that advance understanding of the mechanisms required to induce and/or maintain protective immunity to infectious pathogens, other than HIV, and/or vaccines against such pathogens. The main goal of this FOA is to advance development and application of computational models of immunity that are refined through iterative immunological experimentation to validate and improve the utility and robustness of the computational models.

Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional)

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV.

HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Clinical Trials Units (CTUs) to provide scientific and administrative expertise as well as the infrastructure to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks. Clinical Trials Units will participate in the development of trials and provide clinical sites, local laboratory capacity, and pharmacy support for two or more HIV/AIDS Clinical Trials Networks. 

Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (U01 Clinical Trial Not Allowed)

The objective of this Funding Opportunity Announcement (FOA) is to support the evaluation of early stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical diagnostic algorithms in TB endemic countries. Evaluation studies should focus on: 1) proof-of principle studies of novel diagnostic tests and strategies and 2) provide feedback to diagnostic developers on the performance of the technology and most effective strategy for use of a diagnostic technology in an endemic setting. 


Subscribe to RSS - Colleges/Universities